Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 April 2024 | Story Lacea Loader | Photo Sonia Small
Prof John Klaasen, newly appointed Dean: Theology and Religion at the UFS
Prof John Klaasen, newly appointed Dean: Theology and Religion at the UFS.

The University of the Free State (UFS) has appointed Prof John Klaasen as Dean: Faculty of Theology and Religion from 1 April 2024. 

Prof Klaasen is Professor of Theology and has served two terms as Head of the Department of Religion and Theology at the University of the Western Cape. He also served as Professor in the Kjell Nordstokke Chair in Community Development at VID Specialized University in Norway and is Adjunct Professor at VID Specialized University. 

“With his vast experience and involvement in research projects – nationally as well as internationally – Prof Klaasen will make a significant contribution to the Faculty of Theology and Religion and the university in general. This will also be valuable in support of the university’s Vision 130, which is an expression of our strategic intent to position the institution towards 2034 when the UFS will be 130 years old,” says Prof Francis Petersen, Vice-Chancellor and Principal of the UFS.

As a practical theologian, the intersection between praxis and theory has occupied Prof Klaasen’s research for the past decade. He has researched and published extensively within theology, community development, and narrative. Aspects such as narrative, embedded knowledge, participation, reconciliation, and the non-rational tradition of knowledge are some of the areas that occupy his research outputs.

He is involved in numerous international research projects, which include a COST project with 17 European institutions, a project on reconciliation processes with institutions in Canada and Nordic countries, an international initiative on community development with various institutions in Europe, and a NORPART initiative with Norway and Malawi.

Community engaged scholarship forms a central part of his research and work at the intersection of religion and social justice. Prof Klaasen is involved in various community development projects, including homes for the aged, lay training, water issues, and lay theological education.

His teaching is situated within a socially just pedagogy, which puts the students at the centre of knowledge production. This innovative way of knowledge production intersects students, teachers, and the lecture room within a dynamic space of contextualisation.

“I am grateful for the opportunity to join such a prestigious institution and will endeavour to contribute to Vision 130 through commitment, innovation, trust, and ethical leadership – which represents the university’s commitment to be recognised by our peers and society as a top-tier university in South Africa, ranked among the best in the world,” says Prof Klaasen.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept